EUVIMEDEUVIMED entdecken
Systematische Übersicht

Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations

Taniya Charoensareerat, Weerachai Chaijamorn, Pathakorn Kerdnimith, Nutsinee Kosumwisaisakul, Piyakamol Teeranaew, Dhakrit Rungkitwattanakul, Apinya Boonpeng, Nattachai Srisawat, Sutthiporn Pattharachayakul

Blood Purification · 2023

DOI: 10.1159/000529694 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Blood Purification, 2023. Verfasst von Taniya Charoensareerat und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Siam University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Continuous Renal Replacement Therapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The optimal meropenem dosing regimens in critically ill patients receiving continuous renal replacement therapy (CRRT) based on pharmacokinetic and pharmacodynamic (PD) concepts are not well established. This study aimed to (1) gather the available published pharmacokinetic studies conducted in septic patients receiving CRRT and (2) to define the optimal meropenem dosing regimens in these populations via Monte Carlo simulations.

Methods

We used Medical Subject Headings “meropenem,” “continuous renal replacement therapy,” and “pharmacokinetics” or related terms to identify studies for systematic review. A one-compartment pharmacokinetic model was conducted to predict meropenem levels for the initial 48 h of therapy. The PD targets were 40% of free drug above a threshold of 1 times the minimum inhibitory concentration (MIC) (40% fT > MIC), 4 times the MIC (40% fT > 4MIC), and an additional target of free drug level above 1 times MIC 100% of the time (fT > MIC). The dose that achieved at least 90% of the probability of target attainment (PTA) was defined as an optimal dose.

Results

Twenty-one articles were included for our systematic review. The necessary pharmacokinetic parameters such as volume of distribution and CRRT clearance were cited in 90.5 and 71.4% of articles, respectively. None of the published studies reported completed necessary parameters. A regimen of 750 mg q 8 h was found to be the optimal dose for pre-dilution continuous venovenous hemofiltration and continuous venovenous hemodialysis modality using two effluent rates (25 and 35 mL/kg/h) which achieved the PD target of 40% fT > 4MIC.

Conclusion

None of the published studies showed the necessary pharmacokinetic parameters. PD target significantly contributed to meropenem dosage regimens in these patients. Differing effluent rates and types of CRRT shared similar dosing regimens. Clinical validation of the recommendation is suggested.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Continuous Renal Replacement TherapyHumansMeropenemAnti-Bacterial AgentsMonte Carlo MethodCritical IllnessRenal Replacement Therapy

Stichwörter der Autor:innen

Continuous renal replacement therapyCritically ill patientsMeropenemSystematic review

Substanzen

MeropenemAnti-Bacterial Agents

Autor:innen und Institutionen

  • Faculty of Pharmacy, Siam University, Bangkok, Thailand.
  • CP All Public Company Limited, Bangkok, Thailand.
  • Department of Clinical and Administrative Pharmacy and Sciences Howard University College of Pharmacy, Washington, District of Columbia, USA.
  • School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand.
  • Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

Zitieren

APA

Charoensareerat, T., Chaijamorn, W., Kerdnimith, P., Kosumwisaisakul, N., Teeranaew, P., Rungkitwattanakul, D., Boonpeng, A., Srisawat, N., & Pattharachayakul, S. (2023). Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations. Blood Purification. https://doi.org/10.1159/000529694

Vancouver

Charoensareerat T, Chaijamorn W, Kerdnimith P, Kosumwisaisakul N, Teeranaew P, Rungkitwattanakul D, et al. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations. Blood Purification. 2023. doi:10.1159/000529694

BibTeX
@article{Charoensareerat2023,
  author = {Charoensareerat, Taniya and Chaijamorn, Weerachai and Kerdnimith, Pathakorn and Kosumwisaisakul, Nutsinee and Teeranaew, Piyakamol and Rungkitwattanakul, Dhakrit and Boonpeng, Apinya and Srisawat, Nattachai and Pattharachayakul, Sutthiporn},
  title = {Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations},
  journal = {Blood Purification},
  year = {2023},
  doi = {10.1159/000529694}
}
Kostenlos starten →